Abstract: The application relates to compounds having functional substituents in a specific spatial arrangement, to devices comprising same, and to the preparation and use thereof.
Type:
Grant
Filed:
March 9, 2021
Date of Patent:
April 16, 2024
Assignee:
Merck Patent GmbH
Inventors:
Amir Hossain Parham, Tobias Grossmann, Anja Jatsch, Thomas Eberle, Jonas Kroeber, Christof Pflumm, Lars Dobelmann-Mara
Abstract: Disclosed herein are compounds and compositions useful in the treatment of GLS1 mediated diseases, such as cancer, having the structure of Formula I: Methods of inhibition GLS1 activity in a human or animal subject are also provided.
Type:
Grant
Filed:
April 25, 2022
Date of Patent:
April 16, 2024
Assignee:
Board of Regents, The University of Texas System
Inventors:
Maria Emilia Di Francesco, Philip Jones, Timothy Heffernan, Matthew M. Hamilton, Zhijun Kang, Michael J. Soth, Jason P. Burke, Kang Le, Christopher Lawrence Carroll, Wylie S. Palmer, Richard Lewis, Timothy McAfoos, Barbara Czako, Gang Liu, Jay Theroff, Zachary Herrera, Anne Yau
Abstract: Methods of treating cancer in a patient by administering 5-(1H-indol-3-yl)-1,3-substituted pyrimido[4,5-d]pyrimidine-2,4,7(1H,3H,8H)-trione to a patient in need thereof.
Type:
Grant
Filed:
November 13, 2023
Date of Patent:
April 16, 2024
Assignee:
KING FAISAL UNIVERSITY
Inventors:
Katharigatta N. Venugopala, Rashmi Venugopala, Vinuta Kamat, Amit Kumar
Abstract: The present invention is directed to compounds having the Formula (I), (II), (III), (IV), and (V), compositions thereof, and methods for the treatment of a condition associated with a dysfunction in proteostasis.
Type:
Grant
Filed:
December 17, 2021
Date of Patent:
April 16, 2024
Assignee:
Kineta, Inc.
Inventors:
Matthew Cullen, Sheila Hauck, Bolin Geng, Megan Foley, Cecilia M. Bastos, Benito Munoz, Markus Haeberlein, Bradley Tait
Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Human Respiratory Syncytial Virus (HRSV) or Human Metapneumovirus (HMPV) inhibitors. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HRSV or HMPV infection. The invention also relates to methods of treating an HRSV or HMPV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
Type:
Grant
Filed:
February 24, 2022
Date of Patent:
April 2, 2024
Assignee:
Enanta Pharmaceuticals, Inc.
Inventors:
Adam Szymaniak, Jianming Yu, Kevin McGrath, Xiben Li, Tyler J. Mann, Robert Leon, In Jong Kim, Yat Sun Or, Long Nguyen
Abstract: Provided herein are 4-aminoisoindoline-1,3-dione compounds having the following structure: wherein R, Ring A, and n are as defined herein, compositions comprising an effective amount of a 4-aminoisoindoline-1,3-dione compound, and methods for treating or preventing disorders.
Type:
Grant
Filed:
May 12, 2022
Date of Patent:
April 2, 2024
Assignee:
Celgene Corporation
Inventors:
Matthew D. Alexander, Soraya Carrancio, Matthew D. Correa, Virginia Heather Sharron Grant, Joshua Hansen, Roy L. Harris, Dehua Huang, Timothy S. Kercher, Antonia Lopez-Girona, Mark A. Nagy, Veronique Plantevin-Krenitsky
Abstract: Disclosed herein are salts and solid-state forms of psilocybin, including psilocybin HCl, and salts and solid forms of O-acetylpsilocin, including O-acetylpsilocin fumarate. Also disclosed are methods for making the salts and solid forms and methods for administering the salts and solid forms. The salts and solid forms disclosed herein are useful for treating neurological disease and/or a psychiatric disorder in a subject.
Abstract: The present invention relates to pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of cell proliferative diseases, inflammatory diseases, immunological diseases, cardiovascular diseases and infectious diseases. Furthermore, the present invention is directed towards pharmaceutical compositions containing at least one of the pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives and/or pharmaceutically acceptable salts thereof.
Type:
Grant
Filed:
April 11, 2019
Date of Patent:
April 2, 2024
Assignees:
QURIENT CO., LTD., LEAD DISCOVERY CENTER GMBH
Inventors:
Kiyean Nam, Jaeseung Kim, Yeejin Jeon, Donghoon Yu, Mooyoung Seo, Dongsik Park, Jan Eickhoff, Gunther Zischinsky
Abstract: The invention provides a compound of formula (0): or a pharmaceutically acceptable salt, N-oxide or tautomer thereof; wherein: n is 1 or 2; X is CH or N; Y is selected from CH and C—F; Z is selected from C—Rz and N; R1 is selected from: -(Alk1)t-Cyc1; wherein t is 0 or 1; Optionally substituted C1-6 acyclic hydrocarbon groups R2 is selected from hydrogen; halogen; and C1-3 hydrocarbon groups optionally substituted with one or more fluorine atoms; R3 is hydrogen or a group L1-R7; R4 is selected from hydrogen; methoxy; and optionally substituted C1-3 alkyl; and R4a is selected from hydrogen and a C1-3 alkyl group; wherein Rz, Alk1, Cyc1, L1 and R7 are defined herein; provided that the compound is other than 6-benzyl-3-{2-[(2-methylpyrimidin-4-yl)amino]pyridin-4-yl}-7,8-dihydro-1,6-naphthyridin-5(6H)-one and 3-{2-[(2-methylpyrimidin-4-yl)amino]pyridin-4-yl}-7,8-dihydro-1,6-naphthyridin-5(6H)-one and salts and tautomers thereof.
Type:
Grant
Filed:
April 7, 2021
Date of Patent:
March 26, 2024
Assignee:
OTSUKA PHARMACEUTICAL CO., LTD.
Inventors:
Valerio Berdini, Ildiko Maria Buck, James Edward Harvey Day, Charlotte Mary Griffiths-Jones, Thomas Daniel Heightman, Steven Howard, Christopher William Murray, David Norton, Marc O'Reilly, Alison Jo-Anne Woolford, Michael Liam Cooke, David Cousin, Stuart Thomas Onions, Jonathan Martin Shannon, John Paul Watts
Abstract: A 7-(4-((5-(benzylideneamino)-2-thioxo-1,3,4-thiadiazol-3(2H)-yl)methyl)piperazin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid compound, its synthesis, and its use as an anticancer and/or anti-inflammatory agent.
Type:
Grant
Filed:
November 10, 2023
Date of Patent:
March 26, 2024
Assignee:
KING FAISAL UNIVERSITY
Inventors:
Hany Mohamed Abd El-Lateef Ahmed, Mai Mostafa Khalaf Ali, Antar Ahmed Abdelhamid Ahmed, Amer A. Amer
Abstract: The present disclosure relates to tricyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of the FGFR enzyme and are useful in the treatment of FGFR-associated diseases such as cancer.
Type:
Grant
Filed:
June 8, 2022
Date of Patent:
March 26, 2024
Assignee:
Incyte Corporation
Inventors:
Xin Li, Evan Styduhar, Robert Swyka, Oleg Vechorkin, Wenqing Yao
Abstract: A 4-((2-(2-(2-(4-Methoxyphenyl)-4,5-diphenyl-1H-imidazol-1-yl)acetyl)hydrazono)methyl)benzoic acid compound, its synthesis, and its use as an anticancer agent.
Type:
Grant
Filed:
November 17, 2023
Date of Patent:
March 26, 2024
Assignee:
KING FAISAL UNIVERSITY
Inventors:
Hany Mohamed Abd El-Lateef Ahmed, Mai Mostafa Khalaf Ali, Antar Ahmed Abdelhamid Ahmed, Adel A. Marzouk, Ehab S. Taher, Amira S. Wanas
Abstract: A 4-((2-(2-(2-(4-hydroxyphenyl)-4,5-diphenyl-1H-imidazol-1-yl)acetyl)hydrazono)methyl)benzoic acid compound, its synthesis, and its use as an anticancer agent.
Type:
Grant
Filed:
November 22, 2023
Date of Patent:
March 19, 2024
Assignee:
KING FAISAL UNIVERSITY
Inventors:
Mai Mostafa Khalaf Ali, Hany Mohamed Abd El-Lateef Ahmed, Mohamed Gouda, Antar Ahmed Abdelhamid Ahmed, Adel A. Marzouk, Ehab S. Taher, Amira S. Wanas
Abstract: The invention relates to novel compounds of the formula (I) in which X, R1, R2, R3, V and n have the meanings given above, to the use thereof as acaricides and/or insecticides for controlling animal pests and to methods and intermediates for the preparation thereof.
Type:
Grant
Filed:
June 19, 2019
Date of Patent:
March 12, 2024
Assignee:
Bayer Aktiengesellschaft
Inventors:
Matthieu Willot, Rüdiger Fischer, Dominik Hager, Laura Hoffmeister, David Wilcke, Kerstin Ilg, Ulrich Goergens
Abstract: A compound of formula (I) or an optical isomer thereof, and pharmaceutically acceptable salts, prodrugs, aquo-complexes or non-aqueous-solvent complexes thereof are provided. Experiments prove that, compared with a control compound MGL-3196, the compound of formula (I), which is obtained through specific substitution sites and specific substitution types, is higher in agonist activity to THR-beta and significantly improved in selectivity on THR-beta/THR-alpha. The compound can be used in preparing THR-beta agonist and drugs for treating adaption diseases (including dyslipidemia, hypercholesteremia, non-alcoholic steatohepatitis and non-alcoholic fatty liver disease) applicable to the THR-beta agonist.
Type:
Grant
Filed:
August 20, 2020
Date of Patent:
March 12, 2024
Assignee:
HINOVA PHARMACEUTICALS INC.
Inventors:
Wu Du, Yu Li, Haibo Li, Yuanwei Chen, Chengzhi Zhang, Xinghai Li
Abstract: The disclosure relates to compounds of Formula I or a pharmaceutically acceptable salt thereof, wherein, m, R1-R5, R5A, and L are defined herein. These compounds are useful in methods for stabilizing a mutant PAH protein or reducing blood phenylalanine concentration in a subject suffering from phenylketonuria. In some embodiments, the mutant PAH protein contains at least one R408W, R261Q, R243Q, Y414C, L48S, A403V, I65T, R241C, L348V, R408Q, or V388M mutation. In other embodiments, the mutant PAH protein contains at least one R408W, Y414C, I65T, F39L, R408Q, L348V, R261Q, A300S, or L48S mutation.
Type:
Grant
Filed:
June 27, 2023
Date of Patent:
March 5, 2024
Assignee:
Agios Pharmaceuticals, Inc.
Inventors:
Lucrezia De Pascalis, Heather Jane Finlay, Sandra King, Zenon D. Konteatis, Brian C. Shook
Abstract: The present invention discloses substituted 1-(3,3-difluoropiperidin-4-yl)-8-(pyridin-3-yl)-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one compounds having a capacity to cross the blood-brain barrier; the compound has the structural formula represented by formula (I): The substituted 1-(3,3-difluoropiperidin-4-yl)-8-(pyridin-3-yl)-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one compounds, derivatives and pharmaceutically acceptable salts thereof of the present invention have the ability to cross the blood-brain barrier and are capable of acting as a drug characteristic of a protein kinase inhibitor, in particular for the expression of a protein through an Ataxia-telangiectasia mutated kinase (ATM) and can be used to treat or prevent disorders associated with abnormal protein kinase activity, such as cancer, cancer with brain metastases, cancer with meningeal metastases, glioma, glioblastoma, DIPG, and the like either as monotherapy or combination with other treatment.
Abstract: A series of fused pentacyclic imidazole derivatives, being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders. In particular, the present invention is concerned with 6, 7-dihydro-7, 14-methanobenzimidazo[1, 2-b][2,5]benzodiazocin-5(14H)-one derivatives and analogs thereof.
Type:
Grant
Filed:
November 24, 2020
Date of Patent:
February 27, 2024
Assignees:
UCB Biopharma SRL, Sanofi
Inventors:
Teresa De Haro Garcia, Michael Deligny, Jag Paul Heer, Joanna Rachel Quincey, Mengyang Xuan, Zhaoning Zhu, Daniel Christopher Brookings, Mark Daniel Calmiano, Yves Evrard, Martin Clive Hutchings, James Andrew Johnson, Sophie Jadot, Jean Keyaerts, Malcolm MacCoss, Matthew Duncan Selby, Michael Alan Shaw, Dominique Louis Leon Swinnen, Laurent Schio, Yann Foricher, Bruno Filoche-Romme
Abstract: A solid form of 1-(4-{[6-Amino-5-(4-phenoxy-phenyl)-pyrimidin-4-ylamino]-methy}-4-fluoro-piperidin-1-yl)-propenone, or pharmaceutically acceptable salts thereof, is useful as a BTK inhibitor.
Type:
Grant
Filed:
June 17, 2019
Date of Patent:
January 23, 2024
Assignee:
Merck Patent GmbH
Inventors:
Michael Lange, Clemens Kuehn, Tobias Schlueter, Werner Mederski, David Maillard, Edoardo Burini